Immunocore Holdings (Nasdaq:IMCR) - Aandelenkoers, Nieuws & Analyse

IMCR Overzicht aandelen

Immunocore Holdings plc is een commercieel biotechnologiebedrijf dat zich bezighoudt met de ontwikkeling van immuuntherapieën voor de behandeling van kanker, infectie- en auto-immuunziekten.

Over het bedrijf

IMCR fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Trading at 8.6% below our estimate of its fair value

Revenue is forecast to grow 16.12% per year

Earnings have grown 19.8% per year over the past 5 years

Risicoanalyse

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Immunocore Holdings plc Concurrenten

Kiniksa Pharmaceuticals International

NasdaqGS:KNSA

US$1.6b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.8b

Bicycle Therapeutics

NasdaqGS:BCYC

US$1.6b

MannKind

NasdaqGM:MNKD

US$2.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Immunocore Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$31.70
52 Week Hoogtepunt	US$76.98
52 Week Laag	US$29.72
Bèta	0.72
11 maand verandering	1.90%
3 maanden verandering	-16.73%
1 Jaar Verandering	-33.92%
33 jaar verandering	-20.75%
5 jaar verandering	n/a
Verandering sinds IPO	-26.62%

Recent nieuws en updates

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Recent updates

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Jul 24

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Rendement voor aandeelhouders

	IMCR	US Biotechs	US Markt
7D	-4.9%	-0.7%	-1.6%
1Y	-33.9%	19.8%	30.8%

Rendement versus industrie: IMCR underperformed the US Biotechs industry which returned 20.1% over the past year.

Rendement versus markt: IMCR underperformed the US Market which returned 30.6% over the past year.

Prijsvolatiliteit

Is IMCR's price volatile compared to industry and market?
IMCR volatility
IMCR Average Weekly Movement	5.3%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: IMCR has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: IMCR's weekly volatility (5%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	497	Bahija Jallal	www.immunocore.com

Immunocore Holdings plc is een commercieel biotechnologiebedrijf dat zich bezighoudt met de ontwikkeling van immuuntherapieën voor de behandeling van kanker, infectieziekten en auto-immuunziekten. Het bedrijf biedt KIMMTRAK aan voor de behandeling van patiënten met niet-resectabel of metastatisch uveaal melanoom. Het ontwikkelt ook andere programma's voor oncologie, waaronder tebentafusp dat zich in Fase 2/3 van de klinische studie bevindt voor de behandeling van gevorderd cutaan melanoom.

Immunocore Holdings plc Samenvatting

Hoe verhouden de winst en inkomsten van Immunocore Holdings zich tot de beurswaarde?
IMCR fundamentele statistieken
Marktkapitalisatie	US$1.59b
Inkomsten(TTM)	-US$54.88m
Inkomsten(TTM)	US$280.91m

5.6x

P/S-verhouding

-28.9x

Koers/Winstverhouding

Is IMCR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMCR resultatenrekening (TTM)
Inkomsten	US$280.91m
Kosten van inkomsten	US$199.77m
Brutowinst	US$81.14m
Overige uitgaven	US$136.02m
Inkomsten	-US$54.88m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.10
Brutomarge	28.88%
Nettowinstmarge	-19.53%
Schuld/Eigen Vermogen Verhouding	122.0%

Hoe presteerde IMCR op de lange termijn?

Bekijk historische prestaties en vergelijking

IMCR Overzicht aandelen

Beloningen

Risicoanalyse

Immunocore Holdings plc Concurrenten

NasdaqGS:KNSA

US$1.6b

NasdaqGS:RXRX

US$1.8b

NasdaqGS:BCYC

US$1.6b

NasdaqGM:MNKD

US$2.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Consensus estimates of losses per share improve by 26%

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Recent updates

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Consensus estimates of losses per share improve by 26%

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Second quarter 2024 earnings: EPS exceeds analyst expectations

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Now 20% undervalued after recent price drop

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 26%, revenue upgraded

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated